Arpa Garay Biography and Net Worth

Insider of Moderna

As Chief Commercial Officer, Arpa Garay leads Moderna’s global commercial organization. Ms. Garay joined Moderna from Merck & Co., Inc. (MRK) where she most recently served as Chief Marketing Officer for Merck's Human Health business; she reported to Merck's Chief Executive Officer and was a member of Merck's Executive Committee. In this role, she was responsible for long-term portfolio strategy and global marketing for Merck's in-line and pipeline human health medicines and vaccines, including global market access and pricing strategy, data and analytics, digital marketing, and commercial business development.  During Ms. Garay's 16-year tenure at Merck, she gained broad international enterprise with increasing responsibility across oncology, vaccines, specialty, and chronic care. Prior to her role as Chief Marketing Officer, Ms. Garay served as President of Global Oncology and Digital at MSD. Additionally, she was responsible for data & analytics, digital marketing, and precision medicine worldwide. She also served as President of Global Pharmaceuticals, Analytics, and Digital Marketing; SVP & Head of U.S. Vaccines; and General Manager of Merck & Co. in Norway. Ms. Garay has lived in five countries including Hong Kong, India, Norway, Singapore, and the U.S.  Ms. Garay received her Bachelor of Science in economics from the Massachusetts Institute of Technology, where she focused on medicine, public health and public policy.

What is Arpa Garay's net worth?: The estimated net worth of Arpa Garay is at least $398,409.30 as of December 6th, 2023. Ms. Garay owns 3,690 shares of Moderna stock worth more than $398,409 as of April 27th. This net worth approximation does not reflect any other assets that Ms. Garay may own. Learn More about Arpa Garay's net worth.
How do I contact Arpa Garay?: The corporate mailing address for Ms. Garay and other Moderna executives is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Moderna can also be reached via phone at (617) 714-6500 and via email at [email protected]. Learn More on Arpa Garay's contact information.
Has Arpa Garay been buying or selling shares of Moderna?: Arpa Garay has not been actively trading shares of Moderna in the last ninety days. Most recently, Arpa Garay sold 564 shares of the business's stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $78.34, for a transaction totalling $44,183.76. Following the completion of the sale, the insider now directly owns 3,690 shares of the company's stock, valued at $289,074.60. Learn More on Arpa Garay's trading history.
Who are Moderna's active insiders?: Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (CEO), W. Cornwell (Director), Arpa Garay (Insider), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Jamey Mock (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). Learn More on Moderna's active insiders.
Are insiders buying or selling shares of Moderna?: During the last year, insiders at the sold shares 59 times. They sold a total of 845,770 shares worth more than $97,034,332.71. The most recent insider tranaction occured on April, 24th when Director Noubar Afeyan sold 15,000 shares worth more than $1,624,800.00. Insiders at Moderna own 15.7% of the company. Learn More about insider trades at Moderna.
Information on this page was last updated on 4/24/2024.

Arpa Garay Insider Trading History at Moderna

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/6/2023	Sell	564	$78.34	$44,183.76	3,690

Arpa Garay Buying and Selling Activity at Moderna

Moderna Company Overview

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $107.97

$105.39

$108.19

50 Day Range

MA: $102.54

$86.99

$111.98

2 Week Range

Now: $107.97

$62.55

$142.79

Volume

2,245,667 shs

Average Volume

2,940,287 shs

Market Capitalization

$41.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>